Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)

被引：1
|
作者：
Paz-Ares, L. [1 ,2 ]
Juan-Vidal, O. [3 ]
Carcereny, E. [4 ]
Greillier, L. [5 ]
Navarro, A. [6 ]
Bennouna, J. [7 ]
Santoro, A. [8 ]
Berardi, R. [9 ]
Besse, B. [10 ]
Salvagni, S. [11 ]
Gonzalez, H. [12 ]
de Alvaro, J. [12 ]
Parra-Palau, J. [12 ]
Sanchez-Perez, T. [12 ]
Aronchik, I. [13 ]
Filvaroff, E. [13 ]
Lamba, M. [13 ]
Nikolova, Z. [12 ]
Ponce, S. [1 ,2 ]
机构：
[1] Univ Complutense, Hosp Univ 12 Octubre, H120 CNIO Lung Canc Unit, Madrid, Spain
[2] Ciberonc, Madrid, Spain
[3] Serv Oncol Med, Valencia, Spain
[4] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol Badalona, Oncol Dept, Badalona, Spain
[5] Aix Marseille Univ, AP HM, Marseille, France
[6] Hosp Univ Vall dHebron, Med Oncol, Barcelona, Spain
[7] CHU Nantes, Hop Nord Laennec Nantes, Thorac Oncol Unit, Nantes, France
[8] Ist Clin Humanitas Humanitas Canc Ctr, Dept Med Oncol & Hematol, Rozzano, Italy
[9] Univ Politecn Marche, AOU Osped Riuniti, Ancona, Italy
[10] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[11] Policlin St Orsolae Malpighi, AOU Bolognae, Oncol Dept, Bologna, Italy
[12] Celgene Inst Translat Res Europe, Early Clin Dev, Seville, Spain
[13] Bristol Myers Squibb, Epigenet, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
559P
引用
收藏
页码：S482 / S483
页数：2
相关论文
共 50 条
  • [1] A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results
    Ponce Aix, S.
    Juan-Vidal, O.
    Carcereny, E.
    Trigo, J. M.
    Provencio, M.
    Greillier, L.
    Navarro, A.
    Bennouna, J.
    Santoro, A.
    Berardi, R.
    Besse, B.
    Gonzalez, H.
    de Alvaro, J.
    Parra-Palau, J. L.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S722 - S723
  • [2] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [3] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
  • [4] KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
    Rudin, Charles M.
    Awad, Mark M.
    Navarro, Alejandro
    Gottfried, Maya
    Peters, Solange
    Csoszi, Tibor
    Cheema, Parneet Kaur
    Rodriguez-Abreu, Delvys
    Wollner, Mira
    Czyzewicz, Grzegorz
    Yang, James Chih-Hsin
    Mazieres, Julien
    Orlandi, Francisco J.
    Luft, Alexander
    Gumus, Mahmut
    Kato, Terufumi
    Kalemkerian, Gregory Peter
    Luo, Yiwen
    Pietanza, Maria Catherine
    Kim, Hye Ryun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
    Besse, B.
    Heist, R. S.
    Papadmitrakopoulou, V. A.
    Camidge, D. R.
    Beck, J. T.
    Schmid, P.
    Mulatero, C.
    Miller, N.
    Dimitrijevic, S.
    Urva, S.
    Pylvaenaeinen, I.
    Petrovic, K.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 505 - 511
  • [6] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
    Reinmuth, N.
    DeMarinis, F.
    Leighl, N.
    Sadow, S.
    Davey, K.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
  • [7] A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer
    Li, Shujun
    Liang, Yahai
    Wu, Yanxia
    Huang, Zhong
    Lin, Yanming
    Yang, Zhixiong
    Chen, Hualin
    Wu, Aibing
    JOURNAL OF BUON, 2020, 25 (03): : 1490 - 1496
  • [8] Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer
    Cheng, Ying
    Fan, Yun
    Liu, Xiaoqing
    Liu, Yunpeng
    Liu, Jiwei
    Wang, Dong
    Yu, Yan
    Qin, Shukui
    Liu, Wei
    Huang, Cheng
    Zhang, Helong
    Liang, Jun
    Shi, Jianhua
    Sheng, Lijun
    Yu, Hao
    ONCOLOGY LETTERS, 2019, 17 (05) : 4701 - 4709
  • [9] Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer
    Araujo, Antonio M. F.
    Mendez, Jose C.
    Coelho, Ana L.
    Sousa, Berta
    Barata, Fernando
    Figueiredo, Ana
    Amaro, Teresina
    Azevedo, Isabel
    Soares, Marta
    CANCER INVESTIGATION, 2009, 27 (04) : 391 - 396
  • [10] Phase II study of Celecoxib with Cisplatin plus Etoposide in extensive-stage small cell lung cancer
    Araujo, Antonio M. F.
    Mendez, J. Carlos
    Sousa, Berta A.
    Barata, Fernando
    Figueiredo, Ana
    Azevedo, Isabel M.
    Amaro, Teresina
    Sousa, Maria J.
    Costa, Carla
    Lopes, J. MaChado
    ANNALS OF ONCOLOGY, 2004, 15 : 191 - 191
12345